-
Je něco špatně v tomto záznamu ?
Trends and patterns in EU(7)-PIM prescribing to elderly patients in Germany
I. Selke Krulichová, GW. Selke, PA. Thürmann
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, pozorovací studie
Grantová podpora
PROGRES Q40-09
Univerzita Karlova v Praze
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
CINAHL Plus with Full Text (EBSCOhost)
od 2008-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- charakteristiky bydlení MeSH
- lidé MeSH
- pojistná škoda - přezkoumání statistika a číselné údaje MeSH
- polypharmacy MeSH
- průřezové studie MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sexuální faktory MeSH
- seznam potenciálně nevhodných léčiv statistika a číselné údaje trendy MeSH
- věkové faktory MeSH
- Check Tag
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- Geografické názvy
- Německo MeSH
PURPOSE: The aim of this study was to explore patterns and long-term development in prescribing potentially inappropriate medication (PIM) according to the EU(7)-PIM list to elderly patients in Germany. METHODS: We analysed anonymized German claims data. The study population comprised 6.0 million insured individuals at least 65 years old, including all their prescriptions reimbursed in 2019. For the analysis of long-term development, we used data for the years 2009-2019. Factors associated with PIM prescribing were considered from two perspectives: patient-oriented analysis was performed with logistic regression and prescriber-oriented analysis was performed with multiple linear regression. RESULTS: EU(7)-PIM prevalence was reduced from 56.9% in 2009 to 45.1% in 2019. Average annual volume (DDDs/insured) decreased from 145 in 2009 to 121 in 2019. These figures are substantially greater than those for the older PRISCUS list. The majority of investigated ATC level 2 groups with the highest EU(7)-PIM DDD volume exhibited substantial decreases; moderate increases were found for antihypertensive and urological drugs. Antithrombotics increased strongly with the introduction of direct oral anticoagulants. The most prevalent EU(7)-PIM medication was diclofenac; however, in the age group 85+ years, apixaban was twice as prevalent as diclofenac. Polypharmacy, female sex, age < 90 years, need for nursing care and living in Eastern regions were identified as risk factors. Prescriber specialty was the most marked factor in the prescriber-oriented analysis. CONCLUSION: Although the use of EU(7)-PIMs has been declining, regional differences indicate considerable room for improvement. The comparison with PRISCUS highlights the necessity of regular updates of PIM lists.
AOK Research Institute Berlin Germany
Philipp Klee Institute of Clinical Pharmacology HELIOS University Clinic Wuppertal Wuppertal Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012132
- 003
- CZ-PrNML
- 005
- 20220506125853.0
- 007
- ta
- 008
- 220425s2021 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00228-021-03148-3 $2 doi
- 035 __
- $a (PubMed)33938975
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Selke Krulichová, Iva $u Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic. krulich@lfhk.cuni.cz $1 https://orcid.org/0000000268150780 $7 xx0076216
- 245 10
- $a Trends and patterns in EU(7)-PIM prescribing to elderly patients in Germany / $c I. Selke Krulichová, GW. Selke, PA. Thürmann
- 520 9_
- $a PURPOSE: The aim of this study was to explore patterns and long-term development in prescribing potentially inappropriate medication (PIM) according to the EU(7)-PIM list to elderly patients in Germany. METHODS: We analysed anonymized German claims data. The study population comprised 6.0 million insured individuals at least 65 years old, including all their prescriptions reimbursed in 2 $a PURPOSE The aim of this study was to explore patterns and long term development in prescribing potentially inappropriate medication PIM according to the EU 7 PIM list to elderly patients in Germany METHODS We analysed anonymized German claims data The study population comprised 6 0 million insured individuals at least 65 years old including all their prescriptions reimbursed in 2019 For $a PURPOSE: The aim of this study was to explore patterns and long-term development in prescribing potentially inappropriate medication (PIM) according to the EU(7)-PIM list to elderly patients in Germany. METHODS: We analysed anonymized German claims data. The study population comprised 6.0 million insured individuals at least 65 years old, including all their prescriptions reimbursed in 2019. For the analysis of long-term development, we used data for the years 2009-2019. Factors associated with PIM prescribing were considered from two perspectives: patient-oriented analysis was performed with logistic regression and prescriber-oriented analysis was performed with multiple linear regression. RESULTS: EU(7)-PIM prevalence was reduced from 56.9% in 2009 to 45.1% in 2019. Average annual volume (DDDs/insured) decreased from 145 in 2009 to 121 in 2019. These figures are substantially greater than those for the older PRISCUS list. The majority of investigated ATC level 2 groups with the highest EU(7)-PIM DDD volume exhibited substantial decreases; moderate increases were found for antihypertensive and urological drugs. Antithrombotics increased strongly with the introduction of direct oral anticoagulants. The most prevalent EU(7)-PIM medication was diclofenac; however, in the age group 85+ years, apixaban was twice as prevalent as diclofenac. Polypharmacy, female sex, age < 90 years, need for nursing care and living in Eastern regions were identified as risk factors. Prescriber specialty was the most marked factor in the prescriber-oriented analysis. CONCLUSION: Although the use of EU(7)-PIMs has been declining, regional differences indicate considerable room for improvement. The comparison with PRISCUS highlights the necessity of regular updates of PIM lists.
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a pojistná škoda - přezkoumání $x statistika a číselné údaje $7 D007345
- 650 _2
- $a polypharmacy $7 D019338
- 650 _2
- $a seznam potenciálně nevhodných léčiv $x statistika a číselné údaje $x trendy $7 D000067561
- 650 _2
- $a charakteristiky bydlení $7 D012111
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a sexuální faktory $7 D012737
- 651 _2
- $a Německo $x epidemiologie $7 D005858
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Selke, Gisbert W $u AOK Research Institute (Wissenschaftliches Institut der AOK), Berlin, Germany $1 https://orcid.org/0000000296149875
- 700 1_
- $a Thürmann, Petra A $u Department of Clinical Pharmacology, University of Witten/Herdecke, Witten, North Rhine-Westphalia, Germany $u Philipp-Klee-Institute of Clinical Pharmacology, HELIOS University Clinic Wuppertal, Wuppertal, Germany
- 773 0_
- $w MED00001613 $t European journal of clinical pharmacology $x 1432-1041 $g Roč. 77, č. 10 (2021), s. 1553-1561
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33938975 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506125845 $b ABA008
- 999 __
- $a ok $b bmc $g 1789636 $s 1163333
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 77 $c 10 $d 1553-1561 $e 20210503 $i 1432-1041 $m European journal of clinical pharmacology $n Eur J Clin Pharmacol $x MED00001613
- GRA __
- $a PROGRES Q40-09 $p Univerzita Karlova v Praze
- LZP __
- $a Pubmed-20220425
